Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValiRxLSE:VAL Net Debt Paydown Yield % is 0.52% as of Jul. 15, 2026, which is 30% above its 10-year median of 0.40. The stock has 4 warning signs investors should review. Among 1,162 Biotechnology companies, ValiRx ranks better than 67.99% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, ValiRx's Net Debt Paydown Yield % was 0.52%.
ValiRx (LSE:VAL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for ValiRx's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VAL vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, ValiRx's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ValiRx Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ValiRx's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where ValiRx's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.52% mean?
ValiRx (LSE:VAL) has a Net Debt Paydown Yield % of 0.52% as of Jul. 15, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ValiRx and its competitors. This is 30% above median its historical median of 0.40. Over the past decade, ValiRx's Net Debt Paydown Yield % has ranged from 0.15 to 9.00. According to the industry distribution chart, ValiRx ranks #372 out of 1162 companies in the Biotechnology industry, placing it in the top 32%.
Is ValiRx's Net Debt Paydown Yield % too high?
ValiRx's current Net Debt Paydown Yield % of 0.52% is 30% above median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 9.00. The Biotechnology industry median Net Debt Paydown Yield % is 0.04. ValiRx's value of 0.52% is 1385.7% above this industry median. Based on the distribution chart, ValiRx ranks #372 out of 1162 companies in the Biotechnology industry, which is above the industry midpoint.
How does ValiRx's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #372 out of 1162 companies for Net Debt Paydown Yield %. This puts ValiRx in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.04. ValiRx's value of 0.52% is 1385.7% above this benchmark. Historically, ValiRx's own Net Debt Paydown Yield % has ranged from 0.15 to 9.00 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.04, ValiRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ValiRx's current Net Debt Paydown Yield % of 0.52% is 1385.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ValiRx and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ValiRx's current Net Debt Paydown Yield % is 0.52%, which is 30% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current Net Debt Paydown Yield % of 0.52%. The current Net Debt Paydown Yield % is 0.52%, which is 30% above median its 10-year median of 0.40 and 1385.7% above the Biotechnology industry median of 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current Net Debt Paydown Yield % is 0.52% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VAL has been successfully added to your 
